Having lived with disabling chronic pain for 32 years, one reader discovered a lesser known treatment that has transformed ...

Common reasons for back pain include muscle strain, disk damage, and some chronic conditions ... Shoes with a low heel place less strain on the back. However, some flat shoes with minimal support ...

Predicting who will transition from acute to chronic pain is the “holy grail” of pain neuroscience. A novel biomarker ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

A novel biomarker signature combining PAF and CME predicts chronic pain risk, linking brain activity to individual pain ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

and Chronic Pain Center of Excellence for Canadian Veterans for research on pain management and perioperative care. Source Reference: Olejnik L, et al "Pharmacologic management of acute pain in ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...